

Applicants: Graham P. Allaway et al.  
Serial No.: 09/724,105  
Filed: November 28, 2000  
Page 6

**Response to Restriction Requirement**

In the Office Action, the Examiner restricted claims 1, 6, 8, 9, 11, 13, 17, 19, 22, 26, 27, 31, 36 and 43 to one of the following allegedly distinct inventions under 35 U.S.C. §121:

- I. Claims 1 and 11, drawn to a polypeptide having a sequence corresponding to a portion of a chemokine receptor and a method of using same, classified in class 530, subclass 300;
- II. Claims 6 and 8, drawn to a polypeptide and a composition comprising the polypeptide having a sequence corresponding to a portion of a HIV-1 envelope glycoprotein, classified in class 424, subclass 208.1;
- III. Claim 9, drawn to an antibody or fragment thereof, classified in class 424, subclass 134.1;
- IV. Claims 13 and 17, drawn to a non-chemokine agent and a method of using same, wherein the non-chemokine agent is capable of binding to the chemokine receptor CCR5 and inhibiting the fusion of HIV-1 to a CD4+ cell, classified in class 530, subclass 351;
- V. Claims 19 and 26, drawn to a molecule comprising a non-chemokine agent linked with a ligand, which is capable of binding to a cell surface receptor rather than the chemokine receptor, and a method of using same, classified in class 530, subclass 388.22;
- VI. Claim 22, drawn to a molecule comprising a non-chemokine agent linked to a compound, which is capable of increasing the *in vivo* half-life of the non-chemokine agent,

Applicants: Graham P. Allaway et al.  
Serial No.: 09/724,105  
Filed: November 28, 2000  
Page 7

classified in class 424, subclass 78.91;

VII. Claim 27, drawn to a method for determining whether a non-chemokine agent is capable of inhibiting the fusion of HIV-1 to a CD4+, CCR5+ cell by using a cell to cell fusion assay, classified in class 435, subclass 440;

VIII. Claim 31, drawn to non-human transgenic animal, classified in class 800, subclass 8;

IX. Claim 36, drawn to an agent, which binds to a chemokine receptor but does not affect the receptor's capacity to bind to a chemokine, classified in class 530, subclass 300; and

X. Claim 43, drawn to a method of using same, wherein the agent binds to a chemokine receptor but does not affect the receptor's capacity to bind to a chemokine, classified in class 424, subclass 93.1.

In response to this restriction requirement, applicants hereby elect Group III, claim 9, drawn to an antibody or fragment thereof, with traverse, for prosecution at this time.